Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30240731 | 0.91 | PARP10 (0.41) | MKNK1MKNK2HSD17B1HSD17B2CDK5 | |
| SCHEMBL24933028 | 0.91 | PARP10 (0.41) | MKNK1MKNK2HSD17B1HSD17B2CDK5 | |
| SCHEMBL30240778 | 0.90 | MKNK1 (0.43) | MKNK1MKNK2HSD17B1HSD17B2CSF1R | |
| SCHEMBL24933882 | 0.90 | MKNK1 (0.43) | MKNK1MKNK2HSD17B1HSD17B2CSF1R | |
| SCHEMBL24933735 | 0.87 | HSD17B1 (0.41) | MKNK1MKNK2HSD17B1HSD17B2CDK5 | |
| SCHEMBL30240751 | 0.87 | HSD17B1 (0.41) | MKNK1MKNK2HSD17B1HSD17B2CDK5 | |
| SCHEMBL24933386 | 0.84 | CDC7 (0.38) | MKNK1MKNK2HSD17B1HSD17B2CDK5 | |
| SCHEMBL24933607 | 0.82 | HSD17B2 (0.39) | HSD17B1HSD17B2CDK5CDK5R1 | |
| SCHEMBL24933406 | 0.82 | HSD17B1 (0.41) | HSD17B1HSD17B2CDK5CDK5R1 | |
| SCHEMBL30240675 | 0.82 | HSD17B1 (0.41) | HSD17B1HSD17B2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |